

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8110523

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	THERMOGENESIS HOLDINGS, INC.	08/10/2023
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	SHANGHAI TOTIPOTENTRX INC	
<b>Street Address:</b>	SHANGHAI PILOT FREE TRADE ZONE	
<b>Internal Address:</b>	160 BA SHENG ROAD, BLDG. #7, UNIT #1	
<b>City:</b>	SHANGHAI	
<b>State/Country:</b>	CHINA	
<b>PROPERTY NUMBERS Total: 3</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Patent Number:</b>	9439930	
<b>Patent Number:</b>	9402867	
<b>Patent Number:</b>	9393269	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(303)629-3450	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(303)629-3400	
<b>Email:</b>	docketing-dv@dorsey.com, croft.kimberly@dorsey.com	
<b>Correspondent Name:</b>	KIMBERLY C. CROFT	
<b>Address Line 1:</b>	DORSEY & WHITNEY LLP	
<b>Address Line 2:</b>	1400 WEWATTA STREET, SUITE 400	
<b>Address Line 4:</b>	DENVER, COLORADO 80202	
<b>ATTORNEY DOCKET NUMBER:</b>	499658-00009	
<b>NAME OF SUBMITTER:</b>	KIMBERLY C. CROFT	
<b>SIGNATURE:</b>	/Kimberly C. Croft/	
<b>DATE SIGNED:</b>	08/11/2023	
<b>Total Attachments: 5</b>		
source=20230811_Assignment_TGCESCA to Shanghai TotipotentRX_Executed_P262641 and P262642 Families#page1.tif		
source=20230811_Assignment_TGCESCA to Shanghai TotipotentRX_Executed_P262641 and P262642		

Families#page2.tif

source=20230811\_Assignment\_TGCESCA to Shanghai TotipotentRX\_Executed\_P262641 and P262642

Families#page3.tif

source=20230811\_Assignment\_TGCESCA to Shanghai TotipotentRX\_Executed\_P262641 and P262642

Families#page4.tif

source=20230811\_Assignment\_TGCESCA to Shanghai TotipotentRX\_Executed\_P262641 and P262642

Families#page5.tif

**PATENT**

**REEL: 064570 FRAME: 0394**

**PATENT ASSIGNMENT**

**PARTIES TO THE ASSIGNMENT:**

**Assignors:**

ThermoGenesis Holdings, Inc.  
2711 Citrus Road  
Rancho Cordova, California 95742  
United States of America

Cesca Therapeutics, Inc.  
2711 Citrus Road  
Rancho Cordova, California 95742  
United States of America

State of Incorporation: Delaware

State of Incorporation: Delaware

**Assignee:**

Shanghai TotipotentRx Inc 全能英科医疗科技(上海)有限责任公司  
Shanghai Pilot Free Trade Zone  
160 Ba Sheng Road, Bldg. #7, Unit #1  
Shanghai  
People's Republic of China

State of Incorporation: \_\_\_\_\_

WHEREAS, the Assignor identified above, a corporation organized and existing under the laws of the State indicated above, and having its principal place of business at the address indicated above, is the owner of all right, title, and interest in and to one or more new and useful processes, methods, machines, devices, systems, manufactures, and/or compositions of matter, or new and useful improvements thereof (the "Invention(s)"), disclosed and described in the issued Patent(s) and the Patent Application(s) indicated and identified on the attached Schedule A; and

WHEREAS, Assignee identified above, a corporation organized and existing under the laws of the State indicated above, and having its principal place of business at the address indicated above, desires to acquire the entire right, title, and interest of Assignor in and to the Invention(s), the Patent(s), the Patent Application(s), and in, to, and under any and all Letters Patent to be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor has sold, assigned, and transferred and does hereby sell, assign, and transfer to the Assignee, its successors, legal representatives, and assigns, the entire right, title and interest in and to the Invention(s), the Patent(s), the Patent Application(s), and all divisional, continuation, continuation-in-part, and continuing prosecution applications that claim priority thereto, and any reexamination and reissue applications thereof; all international, regional, and foreign applications that claim priority to, are counterparts of, or otherwise correspond thereto; the Letters Patent, both in the United States and in countries or regions foreign thereto, that may or shall issue or have issued therefrom; any extensions, substitutes, or renewals thereof; the right to claim priority to the filing date of the Patent Application; any right, title, or interest in and to the Inventions under any international conventions; and any and all rights to collect past damages for infringement of any provisional rights and of any and all Letters Patent of the United States and any countries and regions foreign thereto which may be,

shall be, or have been published, which may be, shall be, or have been granted, or which may be lodged (collectively "the Patent Rights"); and

Assignor further authorizes said Assignee, its successors, and assigns, or anyone it may properly designate, to apply for Letters Patent in the U.S. and any and all foreign countries and regions, in its own name if desired, and additionally to claim priority to the filing date(s) of the Patent Application(s) and otherwise take advantage of the provisions of any international conventions; and

Assignor hereby authorizes and requests transfer of the Patent(s), the Patent Application(s), and any further applications, which may be or shall have been filed under the Patent Rights, to the Assignee in accordance herewith and further authorizes and requests any official of any State whose duty consists of issuing patents or other evidence or forms of any industrial property protection issuing from the Patent Rights and all related applications, to issue same to the Assignee, its successors, and assigns in accordance herewith; and

Assignor represents and warrants that Assignor has the right, title, and authority to execute this Assignment and to convey all right, title, and interest in the Patent Rights, and that Assignor has not conveyed nor will convey hereafter all or part of the Patent Rights to a third party, and Assignor hereby covenants and agrees with the Assignee, its successors and assigns, that Assignor will not execute in writing or do any act whatsoever conflicting with these representations; and


Assignor, on behalf of any individuals associated with the filing or prosecution of the Patent Application in Assignor's employ or under its direction or control, agrees to disclose to the Assignee any information, including, but not limited to, prior art references, that Assignor is presently aware of or becomes aware of in the future that would materially affect the patentability of the Invention or the Patent Application or the present or future validity of the Patent Rights; and

Assignor, Assignor's successors, legal representatives, or administrators will at any time upon request, without further or additional consideration, but at the expense of the Assignee, its successors, and assigns, execute such additional writings and do such additional acts as said Assignee, its successors, and assigns, may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for, obtaining, and enforcing any of the Patent Rights, including giving testimony in any proceedings or transactions involving such Patent Rights; and

Assignor further covenants and agrees that this Assignment is effective as of the date of execution of this document by Assignor's representative below.

IN WITNESS WHEREOF, the Assignor hereunto has executed this Assignment upon the date indicated below.


ASSIGNOR: ThermoGenesis Holdings, Inc.

Date: Aug 10, 2023 By: 

Name: CHRIS XU

Title: CEO

ASSIGNOR: Cesca Therapeutics, Inc.

Date: Aug 10, 2023 By: 

Name: CHRIS XU


Title: CEO

The Assignee hereby acknowledges and accepts the foregoing assignment of rights by Assignor.

IN TESTIMONY WHEREOF, the Assignee, by its undersigned officer, confirms its acceptance on the date set forth below.

ASSIGNEE: **Shanghai TotipotentRx Inc**

全能英科医疗科技(上海)有限责任公司

Dated: Aug 10, 2023   
(signature)

By: XIAOCHUN XU  
(printed name of authorized agent of assignee)

Its: Chairman  
(title)

**Schedule A**

Country	Docket No.	Application No.	Filing Date	Patent No.	Issue Date
Hong Kong	P262641.CN-HK.01	16105929.7	May 24, 2016	HK1217911	October 9, 2020
U.S.A.	P262641.US.01	14/296,360	June 4, 2014	9,439,930	September 13, 2016
U.S.A.	P262641.US.02	14/297,565	June 5, 2014	9,402,867	August 2, 2016
U.S.A.	P262641.US.03	14/297,557	June 5, 2014	9,393,269	July 19, 2016
PCT	P262641.WO.01	PCT/US2014/010745	January 8, 2014	-	-
China	P262641.WO-CN.01	201480014602.0	January 8, 2014	ZL201480014602.0	August 27, 2019
India	P262641.WO-IN.01	7120/DELNP/2015	January 8, 2014	426974	March 27, 2023
Japan	P262641.WO-JP.01	2015-552751	January 8, 2014	6525889	May 17, 2019
U.S.A.	P262642.US.01	62/156,126	May 1, 2015	-	-
PCT	P262642.WO.01	PCT/US2016/029863	April 28, 2016	-	-